In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL.

Chronic lymphocytic leukemia-- or CLL-- is a type of cancer ... but because of the change-- called a mutation-- faulty white blood cells that don't work like they should are made instead.

A study of 200 patients with chronic lymphocytic leukemia (CLL) showed a lower rate of severe and serious adverse events ...

Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

BRUIN CLL-321 serves as the confirmatory trial to ... with 54% harboring 17p deletions and/or TP53 mutations, and over 60% with complex karyotype. They had been heavily pretreated as well, with ...

The advent of targeted therapies against FLT3 and IDH1/2 mutations underscores the clinical impact of molecular profiling. Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL ...

The combination’s fixed-duration treatment is intended to achieve deeper remission for treatment-naïve subjects with no drug-resistant mutations ... refractory (r/r) CLL/SLL, r/r marginal ...